PRF Technologies Announces Positive Preclinical Study Results for PRF-110

PRF Technologies Ltd. announced positive results from a preclinical study comparing its lead product candidate, PRF-110, to ZYNRELEF®. The study demonstrated that PRF-110, a ropivacaine-only, NSAID-free formulation, achieved sustained 72-hour analgesic activity comparable to ZYNRELEF® in a preclinical model. PRF-110 is designed for post-operative pain management through direct wound-bed administration, aiming to reduce opioid reliance. The company believes these findings support PRF-110's potential advantages, including a favorable safety profile due to the absence of NSAIDs and ropivacaine's lower cardiac toxicity compared to bupivacaine. These results will inform the next steps in PRF-110's development and regulatory strategy.